Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Extensive-Stage Small-Cell Lung Cancer · Small-Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Pushed back a key date by about 33 months
Since Nov 6, 2026 · was worth 10, fading over time
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 563 (final count)
- Started
- Jun 5, 2024
- Main results expected
- Apr 2, 2030
- Fully finished
- Apr 2, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
OS
Measured over: Up to approximately 3 years
Changes Tremor has spotted
Pushed back the final finish date by about 18 months: Sep 30, 2028 → Apr 2, 2030.
Amgen's late-stage study (Phase 3, a test of whether a treatment works in a larger group of patients) has pushed its final finish date from 2028-09-30 to 2030-04-02, about 18 months later, and it is no longer signing up new patients. A later finish date can be a worry for investors because it may mean the study is moving more slowly than planned, which could point to problems with the trial itself. But delays also happen for ordinary reasons, such as scheduling or paperwork, and the company hasn't said why this one moved, so the change alone doesn't prove anything.
AI-written from the facts above
Spotted
Pushed back the main results date by about 33 months: Jul 5, 2027 → Apr 2, 2030.
Amgen pushed back the expected date for the main results of a late-stage study of its lung cancer drug tarlatamab, from July 2027 to April 2030, which is about 33 months later. Investors often watch changes like this because a delayed result can signal that a trial is taking longer than planned, which may point to slower progress or problems with the study. The change is an ordinary one, though, and companies move these dates for many reasons, so by itself it doesn't show that anything is wrong with the drug or the trial. The company hasn't said why the date moved.
AI-written from the facts above
Spotted
Show details (technical version)
Score inputs
- date_delayed: base 10, now 10, since 2026-11-06, fades (half-life)
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · date_delayed · completion_date
old: "2028-09-30"
new: "2030-04-02"
details: {"months":18} - 2026-11-06 15:29 UTC · date_delayed · primary_completion_date
old: "2027-07-05"
new: "2030-04-02"
details: {"months":32.9}
Trial ID NCT06211036 · record last updated 2026-11-06 · checked 2026-11-09 06:30 UTC